Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data

Roobol, 2010, A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer, Eur Urol, 57, 79, 10.1016/j.eururo.2009.08.025 Kasivisvanathan, 2018, MRI-targeted or standard biopsy for prostate-cancer diagnosis, N Engl J Med, 378, 1767, 10.1056/NEJMoa1801993 Alberts, 2016, Risk-based patient selection for magnetic resonance imaging-targeted prostate biopsy after negative transrectal ultrasound-guided random biopsy avoids unnecessary magnetic resonance imaging scans, Eur Urol, 69, 1129, 10.1016/j.eururo.2015.11.018 Alberts, 2019, Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators, Eur Urol, 75, 310, 10.1016/j.eururo.2018.07.031 Wynants, 2019, Three myths about risk thresholds for prediction models, BMC Med, 17, 192, 10.1186/s12916-019-1425-3 Roobol, 2012, Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators, Eur Urol, 61, 577, 10.1016/j.eururo.2011.11.012 Mannaerts, 2018, Prostate cancer risk assessment in biopsy-naive patients: the Rotterdam Prostate Cancer Risk Calculator in multiparametric magnetic resonance imaging-transrectal ultrasound (TRUS) fusion biopsy and systematic TRUS biopsy, Eur Urol Oncol, 1, 109, 10.1016/j.euo.2018.02.010 Gayet, 2018, Prediction of prostate cancer: external validation of the ERSPC risk calculator in a contemporary Dutch clinical cohort, Eur Urol Focus, 4, 228, 10.1016/j.euf.2016.07.007 Verbeek, 2021, Assessing a patient's individual risk of biopsy-detectable prostate cancer: be aware of case mix heterogeneity and a priori likelihood, Eur Urol Oncol, 4, 813, 10.1016/j.euo.2019.07.012 Steyerberg, 2009 Vickers, 2020, Routine use of magnetic resonance imaging for early detection of prostate cancer is not justified by the clinical trial evidence, Eur Urol, 78, 304, 10.1016/j.eururo.2020.04.016 Padhani, 2020, Platinum opinion counterview: the evidence base for the benefit of magnetic resonance imaging-directed prostate cancer diagnosis is sound, Eur Urol, 78, 307, 10.1016/j.eururo.2020.05.038 van den Bergh RCN, Rouviere O, van der Kwast T, EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guidelines Panel. Re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine use of magnetic resonance imaging for early detection of prostate cancer is not justified by the clinical trial evidence. Eur Urol 2020;78:304–6: prebiopsy MRI: through the looking glass. Eur Urol 2020;78:310–3. Vickers A, Carlsson SV, Cooperberg M. Reply to Roderick C.N. van den Bergh, Olivier Rouviere, and Theodorus van der Kwast's Letter to the Editor re: Andrew Vickers, Sigrid V. Carlsson, Matthew Cooperberg. Routine use of magnetic resonance imaging for early detection of prostate cancer is not justified by the clinical trial evidence. Eur Urol 2020;78:304–6. Prebiopsy MRI: through the looking glass. Eur Urol 2020;78:314–5. Ahmed, 2017, Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study, Lancet, 389, 815, 10.1016/S0140-6736(16)32401-1 Rouvière, 2019, Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study, Lancet Oncol, 20, 100, 10.1016/S1470-2045(18)30569-2 van der Leest, 2019, Eur Urol, 75, 570, 10.1016/j.eururo.2018.11.023 Drost, 2019, Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer, Cochrane Database Syst Rev, 4, CD012663 Drost, 2020, Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer: a Cochrane systematic review and meta-analysis, Eur Urol, 77, 78, 10.1016/j.eururo.2019.06.023 Poyet, 2016, BJU Int, 117, 401, 10.1111/bju.13314 Pereira-Azevedo, 2018, Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome, Transl Androl Urol, 7, 18, 10.21037/tau.2017.12.21 Radtke, 2019, Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS, PLoS One, 14, 10.1371/journal.pone.0221350 Pullen, 2020, External validation of novel magnetic resonance imaging-based models for prostate cancer prediction, BJU Int, 125, 407, 10.1111/bju.14958 Nordström, 2021, Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial, Lancet Oncol, 22, 1240, 10.1016/S1470-2045(21)00348-X Eklund, 2021, MRI-targeted or standard biopsy in prostate cancer screening, N Engl J Med, 385, 908, 10.1056/NEJMoa2100852 Wallstrom, 2021, Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Goteborg prostate cancer screening 2 trial, Eur Radiol, 31, 8692, 10.1007/s00330-021-07907-9 Van Poppel, 2021, Early detection of prostate cancer in 2020 and beyond: facts and recommendations for the European Union and the European Commission, Eur Urol, 79, 327, 10.1016/j.eururo.2020.12.010 Van Poppel, 2021, A European model for an organised risk-stratified early detection programme for prostate cancer, Eur Urol Oncol, 4, 731, 10.1016/j.euo.2021.06.006